Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 1:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–7 of 7 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Age-Related Macular Degeneration
Interventions
E10030, bevacizumab or aflibercept, E10030 sham injection
Drug
Lead sponsor
Ophthotech Corporation
Industry
Eligibility
50 Years and older
Enrollment
645 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
100
States / cities
Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 88 more
Conditions
Diabetic Macular Edema, Cataract
Interventions
Aflibercept injected Pre- and Post-operatively, Aflibercept injected intraoperatively
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
2
States / cities
Atlanta, Georgia
Conditions
Idiopathic Polypoidal Choroidal Vasculopathy
Interventions
Avacincaptad Pegol
Drug
Lead sponsor
Ophthotech Corporation
Industry
Eligibility
50 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Phoenix, Arizona
Completed Phase 2Phase 3 Interventional Results available

Anti-VEGF vs. Prompt Vitrectomy for VH From PDR

NCT02858076
Conditions
Proliferative Diabetic Retinopathy, Vitreous Hemorrhage
Interventions
2-mg Intravitreous Aflibercept Injection, Prompt Vitrectomy Plus Panretinal Photocoagulation
Drug · Procedure
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
60
States / cities
Campbell, California • Glendale, California • Huntington Beach, California + 50 more
Conditions
Diabetic Retinopathy
Interventions
670nm PBM, intravitreous VEGF-inhibitors
Device · Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Completed Phase 3 Interventional Results available

Anti-VEGF Treatment for Prevention of PDR/DME

NCT02634333
Conditions
Diabetic Retinopathy, Diabetic Macular Edema
Interventions
Prompt Sham, Prompt aflibercept, Deferred laser, Deferred aflibercept
Procedure · Drug
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
399 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
81
States / cities
Phoenix, Arizona • Tucson, Arizona • Huntington Beach, California + 68 more
Conditions
Diabetic Macular Edema
Interventions
intravitreous aflibercept, Bevacizumab + Deferred Aflibercept Group
Drug
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
54
States / cities
Campbell, California • Glendale, California • Loma Linda, California + 46 more